


## (S,R,S)-AHPC-C6-NH2

<b>Cat. No.:</b>	HY-136006B		
<b>CAS No.:</b>	2306389-03-5		
<b>Molecular Formula:</b>	C <sub>29</sub> H <sub>43</sub> N <sub>5</sub> O <sub>4</sub> S		
<b>Molecular Weight:</b>	557.75		
<b>Target:</b>	E3 Ligase Ligand-Linker Conjugates		
<b>Pathway:</b>	PROTAC		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (179.29 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM		1.7929 mL	8.9646 mL	17.9292 mL
		5 mM		0.3586 mL	1.7929 mL	3.5858 mL
10 mM			0.1793 mL	0.8965 mL	1.7929 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (4.48 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (4.48 mM); Suspended solution; Need ultrasonic</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (4.48 mM); Clear solution</li> </ol>					

### BIOLOGICAL ACTIVITY

<b>Description</b>	(S,R,S)-AHPC-C6-NH2 (VH032-C6-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	VHL
<b>In Vitro</b>	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[2]</sup> .

---

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

- [1]. Scheepstra M, et al. Bivalent Ligands for Protein Degradation in Drug Discovery. *Comput Struct Biotechnol J*. 2019;17:160-176. Published 2019 Jan 25.
- [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. *Cell Chem Biol*. 2020;27(8):998-985.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA